Huiyu Pharmaceutical (688553.SH): Injection Carfizomib Obtained Drug Registration Certificate.
Huiyu Pharmaceuticals (688553.SH) released an announcement, stating that the company recently received the drug registration certificate for their company product, Carfilzomib for Injection, approved and issued by the National Medical Products Administration. Carfilzomib for Injection is primarily used for the treatment of multiple myeloma.
Huiyu Pharmaceutical (688553.SH) announced that the company recently received the company's product injection card for carfilzomib issued by the National Medical Products Administration. The injection of carfilzomib is mainly used for the treatment of multiple myeloma.
Related Articles

Industrial: How do high oil prices affect US inflation and Federal Reserve actions?

EB SECURITIES: AI inflation is giving birth to a new cycle, and the price increase of optical fiber and copper-clad laminate is driving the growth of industry companies.

Microsoft Corporation (MSFT.US) Azure takes the lead and becomes the first global cloud service provider to begin validating the NVIDIA Corporation Vera Rubin NVL72 system.
Industrial: How do high oil prices affect US inflation and Federal Reserve actions?

EB SECURITIES: AI inflation is giving birth to a new cycle, and the price increase of optical fiber and copper-clad laminate is driving the growth of industry companies.

Microsoft Corporation (MSFT.US) Azure takes the lead and becomes the first global cloud service provider to begin validating the NVIDIA Corporation Vera Rubin NVL72 system.

RECOMMEND

“A+H” Team Continues To Expand Hard Technology Firms Accelerate Global Deployment
11/03/2026

Anti‑Stagflation Theme Guides Hong Kong Allocation Institutions Identify Power And Energy Assets As Short‑Term Core
11/03/2026

U.S. Equities Enter “Always‑On” Trading Era Nasdaq Advances Stock Tokenization Framework
11/03/2026


